News briefing: Incyte bankrolls an early-stage myelofibrosis pair-up with Jakafi; InnoCare gets Chinese approval for lead drug
Looking to further bolster its blockbuster franchise for Jakafi, Incyte has struck a deal to partner up on a new combination approach to treating myelofibrosis.
Incyte is bankrolling a Phase Ib study combining Jakafi with CK0804, Cellenkos’ “cryopreserved CXCR4 enriched, allogeneic, umbilical cord blood-derived T-regulatory cells.” The smaller biotech will carry out the study, leaving Incyte with an option to swoop in and pick up sole development and commercialization rights — if it all works out.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 98,900+ biopharma pros reading Endpoints daily — and it's free.